120,480 Shares in Moderna, Inc. $MRNA Purchased by Mirae Asset Global Investments Co. Ltd.

Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Moderna, Inc. (NASDAQ:MRNA) during the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 120,480 shares of the company’s stock, valued at approximately $23,201,000.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the company. Western Pacific Wealth Management LP purchased a new position in shares of Moderna in the third quarter valued at $29,000. Allied Private Wealth LLC purchased a new position in shares of Moderna in the second quarter valued at $30,000. Archer Investment Corp bought a new stake in Moderna in the second quarter worth $36,000. Ramsey Quantitative Systems bought a new stake in Moderna in the third quarter worth $40,000. Finally, Assetmark Inc. increased its position in Moderna by 35.1% in the first quarter. Assetmark Inc. now owns 801 shares of the company’s stock worth $41,000 after purchasing an additional 208 shares during the last quarter. 75.33% of the stock is currently owned by institutional investors.

Insider Transactions at Moderna

In related news, insider Shannon Klinger sold 3,471 shares of Moderna stock in a transaction dated Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total transaction of $485,766.45. Following the completion of the transaction, the insider directly owned 74,129 shares of the company’s stock, valued at approximately $10,374,353.55. The trade was a 4.47% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, CFO Jamey Mock sold 34,836 shares of Moderna stock in a transaction dated Thursday, September 10th. The stock was sold at an average price of $134.49, for a total transaction of $4,685,093.64. Following the transaction, the chief financial officer directly owned 59,375 shares of the company’s stock, valued at approximately $7,985,343.75. This represents a 36.98% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 197,251 shares of company stock worth $33,875,904. 10.80% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

A number of equities research analysts recently issued reports on the stock. Bradesco Corretora raised shares of Moderna to an “outperform” rating in a research note on Friday, August 28th. Deutsche Bank Aktiengesellschaft initiated coverage on shares of Moderna in a research note on Friday, August 28th. They issued a “hold” rating and a $125.00 price objective for the company. Morgan Stanley boosted their target price on shares of Moderna from $89.00 to $95.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 7th. CLSA upgraded shares of Moderna to an “outperform” rating in a research report on Friday, August 28th. Finally, Wolfe Research upgraded shares of Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Six analysts have rated the stock with a Buy rating, fifteen have given a Hold rating and four have given a Sell rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $107.10.

Moderna Stock Down 0.4%

Shares of MRNA opened at $220.83 on Tuesday. The company has a market cap of $88.16 billion, a PE ratio of -27.64 and a beta of 1.09. The business has a fifty day moving average of $184.00 and a 200 day moving average of $87.42. Moderna, Inc. has a 52-week low of $22.28 and a 52-week high of $254.48. The company has a quick ratio of 2.18, a current ratio of 2.29 and a debt-to-equity ratio of 0.09.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Friday, July 31st. The company reported ($1.97) EPS for the quarter, topping the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million during the quarter, compared to analyst estimates of $102.93 million. During the same period in the previous year, the firm earned ($2.13) earnings per share. Moderna’s quarterly revenue was up 2.1% compared to the same quarter last year. On average, sell-side analysts expect that Moderna, Inc. will post -6.11 EPS for the current year.

About Moderna

Moderna, Inc is a biotechnology company that develops medicines and vaccines using messenger RNA (mRNA) technology. Its platform is designed to instruct cells to produce proteins that can stimulate immune responses or support the treatment of disease. The company’s research programs span infectious diseases, immuno-oncology, rare diseases, autoimmune conditions and other therapeutic areas.

Moderna’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults.